Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other Working Capital Changes (2020 - 2025)

Historic Other Working Capital Changes for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to -$329894.0.

  • Inhibikase Therapeutics' Other Working Capital Changes fell 111132.43% to -$329894.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $264193.0, marking a year-over-year increase of 1325047.29%. This contributed to the annual value of $616523.0 for FY2024, which is 45508.61% up from last year.
  • Inhibikase Therapeutics' Other Working Capital Changes amounted to -$329894.0 in Q3 2025, which was down 111132.43% from -$139351.0 recorded in Q2 2025.
  • Inhibikase Therapeutics' Other Working Capital Changes' 5-year high stood at $759312.0 during Q1 2023, with a 5-year trough of -$1.1 million in Q2 2021.
  • Its 5-year average for Other Working Capital Changes is -$177485.8, with a median of -$157502.0 in 2021.
  • In the last 5 years, Inhibikase Therapeutics' Other Working Capital Changes crashed by 283382.48% in 2021 and then soared by 63754.35% in 2024.
  • Over the past 5 years, Inhibikase Therapeutics' Other Working Capital Changes (Quarter) stood at -$142619.0 in 2021, then crashed by 140.13% to -$342472.0 in 2022, then soared by 71.67% to -$97018.0 in 2023, then soared by 637.54% to $521514.0 in 2024, then crashed by 163.26% to -$329894.0 in 2025.
  • Its last three reported values are -$329894.0 in Q3 2025, -$139351.0 for Q2 2025, and $211924.0 during Q1 2025.